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To help define the immunological epitopes on human growth hormone (hGH), interaction of fragments 
of the hormone with 7 monoclonal antibodies (McAbs) was tudied. Plasmin-digested hGH, containing 
two peptides (hGH1-134 and hGH’41-191 ) joined by a disulphide bond, bound to each McAb with affinity 
similar to that of intact hGH. The purified C-terminal fragment, hGH 141-191, showed low affinity for each 
McAb. The N-terminal fragment, hGH1-‘34, bound withquite high affinity to 2 McAbs (EBl and EB3) 
but not to the other 5. We conclude that residues 1-134 of hGH contain the epitope to which McAbs EBl 
and EB3 bind. 
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1. INTRODUCTION 
Monoclonal antibodies (McAbs) to human 
growth hormone (hGH) have been described in 
[l-3]. Each such antibody may interact with just 
one epitope (determinant) on the monomeric hor- 
mone, but different McAbs may interact with dif- 
ferent epitopes [ 1,4-61. The potential uses of 
McAbs as probes of structure and function make 
it important to define the sites with which they in- 
teract in as much detail as possible. In order to 
help define the epitopes on hGH we have modified 
the hormone by digestion with the enzyme 
plasmin, and have studied the ability of the 
fragments so-produced to bind to a series of 
McAbs. 
hGH’-134 and hGH141-lg1, can be separated by gel 
filtration after reduction and alkylation of 
disulphide bridges. Interaction of the cleaved hGH 
and the separated peptides with 4 McAbs to hGH, 
3 McAbs to human placental lactogen (hPL) 
(which show almost complete cross-reaction with 
hGH [6,8]) and with a polyclonal antiserum to 
hGH has been studied. 
2. MATERIALS AND METHODS 
2.1. Antibodies to hGH 
Plasmin cleaves hGH (a protein with a single 
polypeptide chain of 191 residues) after residues 
134 and 140, liberating a hexapeptide and conver- 
ting the single chain into a two-chain molecule 
linked by a disulphide bridge [7]. Two fragments, 
Abbreviations: hGH, human growth hormone; McAb, 
monoclonal antibody; hPL, human placental lactogen 
Antibodies from 4 hybridoma cell lines (NA27, 
NA39, NA71 and QA68) secreting mouse McAbs 
(IgG) against hGH and from 3 hybridoma cell lines 
(EBl, EB2 and EB3) secreting IgG McAbs against 
hPL were generously provided by Dr J. Ivanyi 
(Department of Experimental Immunobiology, 
Wellcome Research Laboratories, Beckenham, 
Kent BR3 3BS). Their preparation and character- 
ization has been described in [ 1,6,8]. The three an- 
tibodies raised against hPL all show almost com- 
plete cross-reaction with hGH [6,8]. 
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A polyclonal antibody against hGH (RD 15/16) 
was obtained from Wellcome Diagnostics Ltd. 
2.2. Iodination and radioimmunoassay of hGH 
hGH (prepared by the method as in [9]; a 
generous gift of Wellcome Laboratories and the 
DHSS/MRC Joint Advisory Committee) was 
iodinated with Na”‘I as in [4], using a modified 
chloramine T method. ‘251-Labelled hGH was 
purified by gel filtration [4]. It had spec. act. 
40-80 &i//g. 
carried out in slab gels using the discontinuous 
system in [lo]. Amino acid analyses were carried 
out after hydrolysis with 6 N HCl containing a 
trace of phenol (llO’C, 24 h, sealed evacuated 
tube), on a Locarte amino acid analyser. 
3. RESULTS 
3.1. Digestion of hGH with plasmin 
The immunological activity of hGH fragments 
was tested using a liquid phase radioimmunoassay 
system, as in [4], with each of the 8 different an- 
tibodies studied. All samples, standards etc. were 
dissolved in assay buffer containing 0.05 M 
sodium phosphate (pH 7.6), 0.6 mM merthiolate 
and either 0.05% bovine serum albumin or 0.05% 
Tween 20. 
SDS-polyacrylamide gel electrophoresis of 
hGH after digestion with plasmin showed the ex- 
pected pattern (fig.lb, track 7). Two main bands 
were visible, corresponding to components of MI 
- 14300 and < 10000, as would be predicted from 
2.3. Plasmin digestion of hGH and preparation 
and characterization of fragments 
The procedure used was based on that in [7]. 
hGH (5 mg/ml) was dissolved in 60 mM 
NHdHCO3-NH3 buffer (pH 8.0) and digested with 
porcine plasmin (0.2 mg/ml) [from Sigma (Lon- 
don) Ltd.] at 37°C. After 3.25 h the mixture was 
removed and freeze-dried, after addition of the 
protease inhibitor Trasylol (100 KIU/ml) (Bayer 
Ltd., Haywards Heath). For reduction and alkyla- 
tion, 15 mg plasmin-digested hGH was dissolved 
in 2.0 ml 8 M urea [in 0.1 M Tris-HCl buffer (pH 
8.3)], dithiothreitol was added to 7.5 mM (a 
IO-fold molar excess over cystine residues), and the 
solution was flushed with nitrogen for about 5 min 
and left for 1 h at 20°C. Iodoacetamide (recryst- 
allized from water) was added to give 75 mM. 
After 1 h at 2O”C, the reaction mixture was frac- 
tionated directly on a column (93.7 cm x 0.78 cm2) 
of Sephadex G-50 fine, equilibrated and eluted at 
4°C with 10% (v/v) acetic acid. 
The larger fragment produced by plasmin diges- 
tion was rechromatographed on a column (89.2 cm 
x 0.78 cm2) of Sephadex G-100 superfine, 
equilibrated and eluted with 10% (v/v) acetic acid 
at 4°C. This column was calibrated for MI- 
determination using bovine serum albumin, 
ovalbumin and myoglobin as standard proteins of 
known M,. 
Fig.1. (a) Fractionation of plasmin digested hGH, after 
reduction and carbamidomethylation, by gel filtration 
on Sephadex G-50, in lOolo acetic acid; (b) 
polyacrylamide gel electrophoresis in SDS of (1) and (8) 
markers, (2) undigested hGH, (3) fraction A from the 
column, (4) fraction B, (5) fraction C, (6) fraction D, (7) 
Polyacrylamide gel electrophoresis in SDS was plasmin digest of hGH. 
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Fig.2. (a) Fractionation of fraction A from the Sephadex G-50 column (fig.1) by gel filtration on Sephadex G-100 in 
10% acetic acid; (b) polyacrylamide gel electrophoresis in SDS of (1) and (10) markers, (2) undigested hGH, (3) plasmin 
digest of hGH, (4) fraction A from fig.1, (5) fraction E from the G-100 column, (6) fraction F, (7) fraction G, (8) 
fraction H, (9) fraction I. 
the results in [7]. Plasmin-digested hGH was 
reduced, carbamidomethylated and submitted to 
gel filtration (fig.la). Two main peptide- 
containing peaks were detected which correspond- 
cd, as demonstrated by SDS-gel electrophoresis, 
to the two major components seen in plasmin 
digests (fig.lb, tracks 3-6). However, the first 
peak includes not only the large plasmin fragment 
(hGH*-134) but some of the smaller fragment 
(hGH *4t-191), possibly because of continued non- 
covalent association between the two on gel filtra- 
tion. Rechromatography of this component on 
Sephadex G-100 allowed the isolation of the main 
plasmin fragment (hGH’-134) (fig.2a) apparently 
free of the C-terminal component (fig.2b). 
The amino acid compositions of the two plasmin 
fragments corresponded closely to those predicted 
for hGH’-‘34 and hGH’41-‘91. 
3.2. Immunological activity of fragments pro- 
duced by plasmin digestion of hGIi 
The ability of the plasmin fragments to compete 
with ‘2SI-labelled hGH for binding to each of the 
8 antibodies available was studied (table 1). The 
. 
Table 1 
Relative immunopot~cy of fragments produced by plasmin digestion of human growth 
hormone 
Antibody 
NA 27 
NA 39 
QA 68 
NA 71 
EB 1 
EB 2 
EB 3 
Polyclonal antibody 
Immunopotencya 
Unfractionated 
plasmin digest 
hGH’-‘34 hGH 141-191 
2.16 rt 0.18 0.014 f 0.002 0.0062 & 0.0027 
2.06 f 0.12 0.013 f 0.0005 0.0082 st 0.0007 
1.11 f 0.06 0.011 z!z 0.002 0.0063 f 0.0007 
1.28 z.t 0.05 0.0023 k 0.0003 0.0047 f 0.0001 
1.11 i 0.06 0.46 + 0.08 <O.Ol 
1.70 f 0.24 0.024 f 0.004 <O.Ol 
1.49 + 0.03 0.55 * 0.04 < 0.02 
1.17 k 0.07 0.0017 + 0.0004 0.0036 i 0.0005 
a Relative to intact hGH 
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unfractionated plasmin digest possessed an affinity 
for each of the monoclonal antibodies that was at 
least as great as that of the unmodified hormone. 
With every antibody tested, the affinity of the C- 
terminal fragment of hGH (hGH141-191) was low, 
in all cases <2% that of unmodified hGH (table 
1). With 6 of the 8 antibodies tested the affinity of 
hGH’-i3’ for antibody was also low, but with 2, 
EBl and EB3, substantial interaction between an- 
tibody and peptide was observed. When the assay 
buffer used contained the detergent Tween 20 
rather than BSA the immunopotency of all the 
fragments of hGH (relative to intact hGH) was 
decreased, but the ratio of the affinity with EBl 
and EB3 to that with the other antibodies was 
increased. 
4. DISCUSSION 
A McAb to a monomeric protein antigen is ex- 
pected to bind to just one of several possible 
epitopes (antigenic determinants). Modification of 
the antigen by chemical or enzymic means would 
be expected to alter such epitopes selectively and 
hence facilitate definition of the epitopes on an an- 
tigen such as hGH. 
Modi~cation of hGH with plasmin has been 
studied in detail 171. Our plasmin digest of hGH 
contained virtually no unmodified hGH (detec- 
table by polyacrylamide electrophoresis); cleavage 
on the C-terminal side of residues 134 and 140 ap- 
pears to have occurred as expected, yielding a two- 
chain molecule cantoning hGH1-134 linked to 
hGH 141-191 by a disulphide bridge. It is likely that 
the 6-residue peptide hGH’3S-140 separates from 
the two-chain molecule after digestion. The 
disulphide-linked plasmin-digested hGH retained 
an affinity for each of the McAbs studied at least 
as great as that for unmodified hGH, suggesting 
that the region between residues 134 and 141 in 
hGH may not be involved in the determinants for 
any of these antibodies. A polyclonal antibody 
against hGH also showed high affinity for the 
plasmin digested hGH, in agreement with previous 
reports 1111. 
When hGH was reduced, alkylated and frac- 
tionated by gel filtration, peptides corresponding 
to hGH1-134 and hGH141-‘91 (with reduced and 
carbamidomethylated l/2-cystine residues) were ob- 
tained. The first chromatographic separation 
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(Sephadex G-50) gave apparently pure hGH141-191, 
but the N-terminal fragment @IGH’-‘~~) was still 
contaminated with hGH141-‘91, presumably 
because of incomplete dissociation of the two. This 
material retained relatively high immunopotency 
with all the McAbs (37-44% with EBl and EB3; 
6.6-8.6% with the others, relative to hGH). A se- 
cond chromatographic step produced hGH1-134 
apparently free of the C-terminal fragment 
(though a trace contamination cannot be ruled 
out). 
hGH 141-191 bound very poorly to all the an- 
tibodies tested. In most cases a residual binding, 
equivalent o a potency of 0.3- 1% in the radioim- 
munoassay, was detected, but whether this reflects 
an intrinsic activity of hGH’41-‘91 or contamina- 
tion with intact hGH or other fragments cannot be 
determined at this stage. hGH1-134 also showed 
low potency (0.2-2.5%) in the radioimmunoassay 
using most of the antibodies, and again the low 
residual activity could reflect a low intrinsic poten- 
cy or contamination: Synthetic peptides represen- 
ting hGH19-128, hGH73-128 and hGH98-‘28 have 
been shown to bind with low affinity (< 1% that of 
hGH) to 4 other McAbs [12]. However, with two 
McAbs, EBI and EB3, hGH*-‘34 retained a 
relatively high binding ability. EBl and EB3 have 
been shown to bind to a common epitope [a]; 
presumably this is largely retained in hGH1-134 
whereas the epitopes to which the other antibodies 
bind are not. Low binding affinity could be due to 
absence of part of the amino acid sequence com- 
prising the binding site or inability of the amino 
acid sequences present to fold to give the ap- 
propriate conformation for the determinant. Af- 
finity of hGH - ’ 134 for the polyclonal antibody us- 
ed was rather lower than reported for antibodies 
raised in guinea pigs (20% that of hGH [l l] or 
l-3% that of hGH [13-14]), which could be due 
to differences in the antibodies or in the handling 
of the peptides. It is possible that alkylation of the 
I/-cystine residue in hGH1-‘34 (and/or the 3 
I/-cystines in hGH’41-191) contributes to the low 
binding ability of the fragments for some an- 
tibodies, but this seems unlikely since reduced and 
alkylated (but uncleaved) hGH retains high bin- 
ding affinity for all of the antibodies (unpub- 
lished). 
Different results have been obtained using 
fragments obtained by subtilisin digestion of hGH 
Volume 159, number 1,2 FEBS LETTERS August 1983 
and the same McAbs as those used here [15]. The 
larger (15 kDa) fragment, probably hGH’-13’ 
(possibly mixed with some larger peptides) retained 
ability to bind to all of the McAbs tested, though 
binding to NA71 was relatively weak. In addition, 
EBl and EB3 also bound to the smaller subtilisin 
fragment (7 kDa) corresponding approximately to 
hGH’40-1g1. The differences between our results 
and those in [15] may be due to differences in the 
detailed structures of the fragments studied, but 
they could also be due partly to the use of different 
methods for detection of immunoactivity. 
ACKNOWLEDGEMENTS 
We thank Dr J. Ivanyi for the generous gift of 
the monoclonal antibodies used in this work and 
for helpful criticism of the manuscript. We also 
thank Mrs Eileen Willis for skilled preparation of 
the manuscript and the Medical Research Council 
for financial support. 
REFERENCES 
[l] Ivanyi, J. and Davies, P. (1980) Mol. Immunol. 17, 
287-290. 
[2] Bundesen, P.G., Drake, R.G., Kelly, K., Worsley, 
I.G., Friesen, H.G. and Sehon, A.H. (1980) J. 
Clin. Endocrinol. Metab. 51, 1472-1474. 
[3] Retegui, L.A., DeMeyts, P. and Masson, P.L. 
(1982) Prot. Biol. Fluids 29, 827-832. 
[4] Wallis, M., Surowy, T.K. and Ivanyi, J. (1982) 
Mol. Cell. Endocrinol. 28, 363-372. 
[5] Cadman, H.F., Wallis, M. and Ivanyi, J. (1982) 
FEBS Lett. 137, 149-152. 
[6] Ivanyi, ,.J. (1982) in: Monoclonal Hybridoma 
AntibojIres: Techniques and Applications (Hurrell, 
J.G.R. ed) pp.59-79, CRC Press, Boca Raton FL. 
[7] Li, C.H. and GrBf, L. (1974) Proc. Natl. Acad. Sci. 
USA 71, 1197-1201. 
[8] Ivanyi, J. and Davies, P. (1982) Prot. Biol. Fluids 
29, 855-860. 
191 Lumley Jones, R., Benker, G., Salacinski, P.R., 
Lloyd, T.J. and Lowry, P.J. (1979) J. Endocrinol. 
82, 77-86. 
[lo] Laemmli, U.K. (1970) Nature 227, 680-685. 
[l l] Clarke, W.C., Hayashida, T. and Li, C.H. (1974) 
Arch. Biochem. Biophys. 164, 571-574. 
[12] Retegui, L.A., Milne, R.W., Cambiaso, C.L. and 
v31 
[I41 
1151 
Masson, P.L. (1982) Mol. Immunol. 19, 865-875. 
Li, C.H. (1975) Proc. Natl. Acad. Sci. USA 72, 
3878-3882. 
Mills, J.B., Kostyo, J.L., Reagan, C.R., Wagner, 
S.A., Moseley, M.H. and Wilhelmi, A.E. (1980) 
Endocrinology 107, 391-399. 
Aston, R. and Ivanyi, J. (1983) EMBO J. 2, 
493-497. 
245 
